News

JIC Venture Growth Investments (VGI) has announced that VGI invested in Aculys Pharma, Inc. (“Aculys Pharma”, Representative Director and CEO: Kazunari Tsunaba), a biopharmaceutical company, through its JIC Venture Growth Fund 1 (VGF1).

Aculys Pharma develops and commercializes novel pharmaceuticals and provides innovations for better medical care to patients, their families, healthcare professionals, and society in the fields of neurology and psychiatry. The company has been licensed in two assets, pitolisant, Best in Class treatment in sleep disorder and the first nasal spray formulation (diazepam) in Japan for epileptic seizures. Aculys Pharma is conducting aPhase 1 clinical trial of pitolisant in Japan and preparing clinical trials for the anti-epileptic drug.

VGI’s investment enables to address the “drug lag” issue for innovative new medicines that fail to reach patients in Japan. Moreover, beyond the development and commercialization of new medicines, Aculys Pharma is committed to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease. The company looks to form comprehensive “beyond the pill” solutions through cross-sectional partnerships using new technologies to enhance the patient experience.

With VGI’s financing, Aculys Pharma will deliver innovative medicines for neurological and psychiatric disease and create leading-edge successful precedence in digital transformation in pharmaceutical industry. Furthermore, VGI aims to activate biotech ecosystem in Japan.

^{The information contained in this notice is current at the time of publication and subject to change without notice.}